中华现代护理杂志
中華現代護理雜誌
중화현대호리잡지
CHINESE JOURNAL OF MODERN NURSING
2011年
24期
2892-2894
,共3页
张贺真%周学琴%王爱丽%梁莉%罗捷
張賀真%週學琴%王愛麗%樑莉%囉捷
장하진%주학금%왕애려%량리%라첩
抗生素%药品不良反应/事件%分析
抗生素%藥品不良反應/事件%分析
항생소%약품불량반응/사건%분석
Antibacterial agents%Adverse drug reactions/events(ADR/ADE)%Analysis
目的 分析急诊科428例抗菌药品不良反应/事件(ADR/ADE)报告的相关因素,了解抗生素ADR/ADE发生特点及规律,为临床护理安全、有效、合理用药提供参考。方法 对我院急诊科2007年1月至2010年12月收集到的428例抗生素ADR/ADE报告数据进行回顾性统计分析。结果 428例抗菌药品ADR/ADE报告中,女性多于男性,<15岁患儿占14.26%,>50岁患者占61.68%;头孢菌素类居首位占55.85%;静脉点滴占89.96%;主要临床表现为皮肤及其附件、消化系统、全身性损害等。结论 加强抗生素ADR/ADE监测及护理工作,减少或者避免ADR/ADE的发生,确保临床护理安全、有效、合理用药。
目的 分析急診科428例抗菌藥品不良反應/事件(ADR/ADE)報告的相關因素,瞭解抗生素ADR/ADE髮生特點及規律,為臨床護理安全、有效、閤理用藥提供參攷。方法 對我院急診科2007年1月至2010年12月收集到的428例抗生素ADR/ADE報告數據進行迴顧性統計分析。結果 428例抗菌藥品ADR/ADE報告中,女性多于男性,<15歲患兒佔14.26%,>50歲患者佔61.68%;頭孢菌素類居首位佔55.85%;靜脈點滴佔89.96%;主要臨床錶現為皮膚及其附件、消化繫統、全身性損害等。結論 加彊抗生素ADR/ADE鑑測及護理工作,減少或者避免ADR/ADE的髮生,確保臨床護理安全、有效、閤理用藥。
목적 분석급진과428례항균약품불량반응/사건(ADR/ADE)보고적상관인소,료해항생소ADR/ADE발생특점급규률,위림상호리안전、유효、합리용약제공삼고。방법 대아원급진과2007년1월지2010년12월수집도적428례항생소ADR/ADE보고수거진행회고성통계분석。결과 428례항균약품ADR/ADE보고중,녀성다우남성,<15세환인점14.26%,>50세환자점61.68%;두포균소류거수위점55.85%;정맥점적점89.96%;주요림상표현위피부급기부건、소화계통、전신성손해등。결론 가강항생소ADR/ADE감측급호리공작,감소혹자피면ADR/ADE적발생,학보림상호리안전、유효、합리용약。
Objective To learn the adverse drug reactions/events (ADR/ADE) occurred in the characteristics and rules for clinical safe, effective and rational use of available information by analysis of 428antibacterial agents ADR/ADE Reports. Methods 428 antibacterial agents ADR/ADE Reports were statistical analyzed from Jan 1. 2007 to Dec 31. 2010 in our hospital. Results 428 cases of antibacterial agents ADR/ADE, females was slightly more than males; patients between 50 to 83 years old age were accounted for the majority (264 cases,61.68% ) ;the cases that caused by cephalosporins were accounted for the most(239 case,55.85% ),385 case that administered intravenously were accounted for the majority (89. 96% ); antibacterial agents ADR/ADE main clinical manifestations of anaphylactic shock, respiratory, systemic and central nervous system damage. Condusions Strengthening antibacterial agents ADR/ADE monitoring, to decrease the occurrence of Serious ADR/ADE and ensure clinical safety, effective, rational use of drug.